Navigation Links
Organovo Reports Q1 Fiscal 2014 Results, Provides Business Update
Date:8/12/2013

SAN DIEGO, Aug. 12, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo") a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported on its financial results for the three-month period ended June 30, 2013 and provides a business update.

Recent Corporate Highlights

  • Presented data on first fully cellular 3D Bioprinted Liver Tissue
  • Listed common stock on the NYSE MKT
  • Successfully completed $46.6 million public offering
  • Appointed Tamar D. Howson to the Company's Board of Directors 
  • Nominated Richard Heyman Ph.D. for election to the Board of Directors at the upcoming Annual Meeting
  • Changed fiscal year-end from December 31st to March 31st
  • Organovo and Methuselah Foundation Announced Funding of Bioprinting Research at Research Institutions
  • On April 26th, Organovo described the first fully cellular 3D bioprinted liver tissue, having presented data on its  in vitro three-dimensional liver at the 2013 Experimental Biology conference in Boston, Massachusetts. For the first time, human liver tissues were generated that were truly three-dimensional, being up to 500 microns in thickness in the smallest dimension, and consisting of multiple cell types arranged in defined spatial patterns that reproduce key elements of native tissue architecture and demonstrated excellent functional characteristics that replicates human biology better than what has come before. 

    On July 9th, Organovo announced that its common stock had been approved for listing on the New York Stock Exchange MKT.  Trading commenced on the NYSE MKT on July 11th, and Company's CEO Keith Murphy rang the opening bell at the NYSE on July 15 th.

    On August 7 th, Organovo successfully completed a public offering in which it raised gross pro
    '/>"/>

    SOURCE Organovo Holdings, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
    2. Organovo Announces the Nomination of Richard A. Heyman to Board of Directors
    3. Organovo Rings Opening Bell On New York Stock Exchange
    4. OTC Markets Group Congratulates Organovo Holdings on Move to NYSE MKT
    5. Organovo To List Common Stock On New York Stock Exchange MKT
    6. Organovo Appoints Tamar D. Howson to Board of Directors
    7. Organovo to Present at the 12th Annual Needham Healthcare Conference
    8. Organovo Partners With ZenBio to Create 3D Tissue Models
    9. Organovo Holdings, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    10. Organovo Reports Q3 2012 Financial Results, Provides Business Update
    11. Organovo To Present At Lazard Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... (PRWEB) October 30, 2014 Spartan Bioscience ... Spartan RX CYP2C19 System . It detects CYP2C19 genetic ... cheek swab. , The Spartan RX CYP2C19 System is ... has been approved in Canada. Due to the system’s ... may be used by healthcare professionals such as doctors, ...
    (Date:10/30/2014)... Avure Technologies celebrates a year of success and the one-year ... of high volume High Pressure Processing (HPP) systems. , “We’re ... PackExpo this year, which is where we first announced the ... CEO at Avure. “Sales of the new Avure machine are ... challenges of market demand for higher throughput. We sold our ...
    (Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
    (Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. ... will hold a conference call and live audio webcast ... to discuss its third quarter 2014 financial results. ... call by dialing (888) 347-1165 for domestic callers or ... be webcast live under the investor relations section of ...
    Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
    ... ET, LOS ANGELES, Aug. 31 Signalife, Inc. (Amex:,SGN), Lowell ... update since his matriculation into the Presidency,last month: 1. Dr. ... positions that were producing no revenue whatsoever and no ... Company, in his view. That was done ...
    ... Aug. 30 Cepheid (Nasdaq:,CPHD) will present at ... the Four Seasons Hotel, Boston, September 5 to ... Senior Vice President, Finance and,Chief Financial Officer, John ... on,September 7. The webcast, along with accompanying ...
    ... ON, Aug. 30 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated products ... subsidiary, YM BioSciences USA,Inc. ("YM-USA") has been cleared ... initiate a Phase II trial investigating nimotuzumab in ...
    Cached Biology Technology:Signalife Provides Corporate Update 2Signalife Provides Corporate Update 3Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 2YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 3YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 4YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 5
    (Date:10/29/2014)... 2014 — Cambridge, MA and Hebei, China — BGI ... high quality sequencing of the Jujube genome. Jujube is ... and the Jujube genome is particularly difficult to sequence ... factors. It is the first time that a genome ... study has been recently published in Nature ...
    (Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
    (Date:10/28/2014)... novel environment are linked to individual differences in ... completed at the University of Eastern Finland and ... study used novel, long-term observations of individual behaviour ... if behaviours predict the vulnerability to fishing in ... rearing environments. Based on the results, it ...
    Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3Fish 'personality' linked to vulnerability to angling 2
    ... is the primary component of nursery container substrates in ... widely used organic material is prompting researchers to investigate ... James E. Altland and Charles Krause of the USDA ... Development Center was designed to determine if ground switchgrass ...
    ... statistics buried within patient records or detailed in newspaper ... patterns, allowing the discovery of trends that were previously ... use of interactive maps and graphs, combined with word ... events like the spread of Swine flu," said Frank ...
    ... the Braunschweiger Helmholtz-Zentrums fr Infektionsforschung (Helmholtz Center for ... bacterial communities are able to support the degradation ... collaboration of thirteen partners from nine countries. Research ... today at the HZI. The significance of this ...
    Cached Biology News:Switchgrass proves viable as nursery container substrate 2Switchgrass proves viable as nursery container substrate 3Visualization of geographic patterns may predict spread of disease 2Improving the degradation of toxic hydrocarbons 2
    RABBIT ANTI AMPHOTERIN...
    Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
    ... by R. Edwards (1996) • ... types of immunoassays, including RIA, ... and on the photoluminescent and ... information is also given on ...
    ... contains the basic components required for the ... and recombinant Feline IL-10 in cell culture ... materials to run ELISAs on approximately fifteen ... are met: The assay is run ...
    Biology Products: